Wisconsin joins federal lawsuit against Hims & Hers telehealth provider

Wisconsin joined a federal lawsuit against Hims & Hers Health, alleging the telehealth provider shared customer health data with Meta and Snapchat, and engaged in deceptive subscription practices. The state seeks an injunction and restitution. Hims denies wrongdoing, stating it provides clear information to customers. The FTC and six other states are also involved.

Original reporting
Published Nov 13, 2026, 4:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 5:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wisconsin joins federal lawsuit against Hims & Hers telehealth provider — source image
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The suit alleges sharing sensitive health information with ad and social platforms (including Meta and Snapchat), charging for prescriptions soon after intake, and making cancellations difficult, with Wisconsin seeking a permanent injunction and restitution.

02

Market read

Adds a new state plaintiff to an FTC case, increasing enforcement credibility and the probability of injunctive relief or restitution claims.

03

What to watch

The article does not quantify damages or specify likelihood of an injunction, so traders should watch for procedural milestones (motions, discovery, settlement talks) rather than assuming immediate operational disruption.

Relevance 7/10Novelty 6/10Timing: today, as the lawsuit expansion is newly announced

Background

Wisconsin Attorney General Josh Kaul announced the state is joining an FTC-led federal lawsuit targeting Hims & Hers’ telehealth marketing and data practices.

Company-level read

Ticker impact

$HIMSBearishMedium confidence
Context

Wisconsin is joining a federal lawsuit against Hims & Hers alleging it shared sensitive customer health data with third-party ad platforms including Meta and Snapchat.

Expected impact

Likely downside bias as markets price in legal overhang and potential remedies tied to privacy and subscription practices.

Evidence & confidence

The article describes a new state joining the FTC-led case and alleges specific privacy and billing conduct, increasing perceived enforcement intensity even without a stated settlement or damages figure.

Market effects

Heightens scrutiny of DTC telehealth and digital advertising data-sharing practices, potentially raising compliance and marketing-data governance costs across the sector.

US state-level participation signals broader enforcement momentum beyond the FTC, increasing perceived legal tail risk for similar providers serving multiple states.

Moderate, as privacy enforcement themes can spill over to other jurisdictions’ consumer-protection and data-privacy regimes.

Counterpoint

Hims & Hers may argue its privacy policy and disclosures were adequate, and litigation outcomes can take time, limiting near-term financial impact.

Key entities

  • Hims & Hers Health

    Telehealth provider accused of privacy and subscription-practice violations in a federal lawsuit joined by Wisconsin.

  • Federal Trade Commission

    Co-plaintiff in the federal action alleging consumer-protection violations.

  • Wisconsin Department of Justice

    Announced Wisconsin’s participation and the alleged conduct in the amended complaint.

  • Meta

    Named as a recipient of customer health information via third-party advertising platforms.

  • Snapchat

    Named as the owner of Snapchat, also alleged to receive customer health information.

Related articles

$HIMSMed

Canaccord reiterates Hims & Hers stock rating on peptide launch

Canaccord Genuity reiterated a Buy rating and $40 price target for Hims & Hers Health (HIMS) after its launch of Peptides+ treatment line. The company reported Q3 revenue of $890M, up 49% YoY, but saw a subscriber decline. Analysts have mixed views on its outlook, with some lowering price targets due to subscriber losses and others optimistic about future growth.

$HIMSHighAI 8/10

Should Hims & Hers Stock's Drop After Earnings Worry You?

Hims & Hers Health (HIMS) stock dropped 16.6% after reporting Q3 2026 earnings. Revenue of $890M missed estimates by 2.2%, and EPS was -$0.10 vs. expected $0.06 profit. Subscribers fell by 100,000 to 2.8M. Management cut full-year EBITDA and revenue forecasts, citing marketing adjustments and delayed revenue recognition.

$HIMSHighAI 8/10

Hims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%

Hims & Hers reported Q3 2026 revenue of $890.4M, up 49% YoY, but gross margin fell to 57% from 74%. Net loss was $33M vs. $15.8M net income a year ago. Adjusted EBITDA rose to $82.4M. The company forecasts Q4 revenue of $875M-$895M and full-year revenue of $3.13B-$3.15B, but lowered adjusted EBITDA guidance to $257M-$277M.